The Relevance of the Ratio of Pulmonary Arterial Diameter to Aortic Diameter Exceeding One with Brain Natriuretic Peptide and Inflammatory Factors in Patients with Acute Exacerbation of COPD_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

ZhangMing , PengXiaying ,  LiuShouzhi ,  LiangZongan

Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu, Sichuan, 610041, China;

Corresponding?author：

LiuShouzhi, Email: LSZ54@163.com; LiangZongan, Email: liangzongan@hotmail.com

Keywords：

Chronic obstructive pulmonary disease; Acute exacerbation; Pulmonary hypertension; Brain natriuretic peptide

DOI：

10.7507/1671-6205.2015063

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To explore the relevance of the ratio of pulmonary arterial diameter to aortic diameter exceeding one (PA:A>1) with brain natriuretic peptide (BNP) and inflammatory factor levels in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods From August 2013 to December 2013,95 inpatients with AECOPD in West China Hospital were divided into two groups according to the ratio of pulmonary arterial diameter to aortic diameter. The clinical data of the patients were collected. Meanwhile,arterial blood gas,plasma levels of BNP,C-reactive protein (CRP),and interleukin-6 (IL-6) within 24 hours were measured. Results The plasma BNP level was 2005(483-4582)ng/L in the group with PA:A>1,and 404(137-1224)ng/L in the group with PA:A<1. There was significant difference in plasma BNP level between two groups (P<0.01). There was no significant difference in CRP or IL-6 level between two groups (P>0.05). Conclusion The ratio of pulmonary arterial diameter to aortic diameter is correlated with BNP level in patients with AECOPD,but is not correlated with CRP or IL-6.

Citation： ZhangMing, PengXiaying, LiuShouzhi, LiangZongan. The Relevance of the Ratio of Pulmonary Arterial Diameter to Aortic Diameter Exceeding One with Brain Natriuretic Peptide and Inflammatory Factors in Patients with Acute Exacerbation of COPD. Chinese Journal of Respiratory and Critical Care Medicine, 2015, 14(3): 255-259. doi: 10.7507/1671-6205.2015063 Copy

1.	?Murray CJ,Lopez AD.Alternative projections of mortality and disability by cause 1990-2020:Global Burden of Disease Study. Lancet,1997,349:1498-1504.
2.	Ng CS,Wells AU,Padley SP. A CT sign of chronic pulmonary arterial hypertension:the ratio of main pulmonary artery to aortic diameter. J Thorac Imaging,1999,14:270-278.
3.	Iyer AS,Wells JM,Vishin S,et al. CT scan-measured pulmonary artery to aorta ratio and echocardiography for detecting pulmonary hypertension in severe COPD.Chest,2014,145:824-832.
4.	高新海,徐仲卿,趙文穗. 血漿氨基末端腦鈉肽水平與不同程度慢性阻塞性肺疾病肺動脈高壓的相關性. 廣東醫學,2011,32:1150-1151.
5.	王同生,毛毅敏,孫玉霞,等. 白介素-6 和內皮素-1 在慢性阻塞性肺疾病合并肺動脈高壓患者中的表達. 實用醫學雜志,2012,28:1977-1979.
6.	Chaouat A,Savale L,Chouaid C,et al. Role for interleukin-6 in COPD-related pulmonary hypertension. Chest,2009,136:678-687.
7.	MacIntyre N,Huang YC. Acute exacerbations and respiratory failure in chronic obstructive pulmonary disease. Proc Am Thorac Soc,2008,5:530-535.
8.	荊志成. 2010 年中國肺高血壓診治指南.中國醫學前沿雜志 (電子版),2011,3:62-81.
9.	Wells JM,Washko GR,Han MK,et al. Pulmonary arterial enlargement and acute exacerbations of COPD. N Engl J Med,2012,367:913-921.
10.	劉鵬,郭順林,雷軍強,等. 慢性阻塞性肺疾病相關肺動脈高壓的多層螺旋CT評價. 中華結核和呼吸雜志,2012,35:264-268.
11.	高靳,余建群,白紅利,等. 慢性阻塞性肺部疾病病程與肺動脈直徑變化關系的多層螺旋CT評價. 實用放射學雜志,2009,25:332-337.
12.	Committee GS. Global strategy for the diagnosis,management,and prevention of chronic obstructive pulmonary disease (updated 2013). www.goldcopd.org.
13.	Buist AS,McBurnie MA,Vollmer WM,et al. International variation in the prevalence of COPD (the BOLD Study):a population-based prevalence study.Lancet,2007,370:741-750.
14.	Zhong N,Wang C,Yao W,et al. Prevalence of chronic obstructive pulmonary disease in China:a large,population-based survey. Am J Respir Crit Care Med,2007,176:753-760.
15.	Jensen HH,Godtfredsen NS,Lange P,et al. Potential misclassification of causes of death from COPD. Eur Respir J,2006,28:781-785.
16.	Sims MW,Margolis DJ,Localio AR,et al. Impact of pulmonary artery pressure on exercise function in severe COPD. Chest,2009,136:412-419.
17.	Kessler R,Faller M,Fourgaut G,et al. Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med,1999,159:158-164.
18.	Parola D,Romani S,Petroianni A,et al. Treatment of acute exacerbations with non-invasive ventilation in chronic hypercapnic COPD patients with pulmonary hypertension. Eur Rev Med Pharmacol Sci,2012,16:183-191.
19.	Minai OA,Chaouat A,Adnot S. Pulmonary hypertension in COPD:epidemiology,significance,and management pulmonary vascular disease:the global perspective. Chest,2010,137(6 Suppl):39S-51S.
20.	Hoeper MM,Lee SH,Voswinckel R,et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol,2006,48:2546-2552.
21.	Hill NS,Klinger JR,Warburton RR,et al. Brain natriuretic peptide:possible role in the modulation of hypoxic pulmonary hypertension.Am J Physiol,1994,266:308-315.
22.	Inoue Y,Kawayama T,Iwanaga T,et al. High plasma brain natriuretic peptide levels in stable COPD without pulmonary hypertension or cor pulmonale. Intern Med,2009,48:503-512.
23.	Sormunen P,Kallio MJ,Kili IT,et al.C-reactive protein is useful in distinguishing Gram stain negative bacterial meningitis from viral meningitis in children.Pediater,1999,134:725-729.
24.	王維,黃志峰,鄧穗德.2 型糖尿病患者血清超敏C反應蛋白的表達特性.現代醫院,2005,5:20-22.
25.	趙宇.超敏C反應蛋白在慢性阻塞性肺疾病并發肺動脈高壓中的意義.實用醫技雜志,2008,15:2761-2763.
26.	Humbert M,Monti G,Brenot F,et al.Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension.Am J Respir Crit Care,1995,151:1628-1631.
27.	Golembeski SM,West J,Tada Y,et al. Interleukin-6 causes mild pulmonary hypertension and augments hypoxia-induced pulmonary hypertension in mice. Chest,2005,128(6 Suppl):572S-573S.
28.	Joppa P,Petrasiva D,Stancak B,et al. Systemic inflammation in patients with COPD and pulmonary hypertension. Chest,2006,130:326-333.
29.	Guignabaert C,Raffestin B,Benferhat R,et al.Serotonin transporter inhibition prevents and reverses monocrotaline induced pulmonary hypertension in rats. Circulation,2005,111:2812-2819.

1. ?Murray CJ,Lopez AD.Alternative projections of mortality and disability by cause 1990-2020:Global Burden of Disease Study. Lancet,1997,349:1498-1504.
2. Ng CS,Wells AU,Padley SP. A CT sign of chronic pulmonary arterial hypertension:the ratio of main pulmonary artery to aortic diameter. J Thorac Imaging,1999,14:270-278.
3. Iyer AS,Wells JM,Vishin S,et al. CT scan-measured pulmonary artery to aorta ratio and echocardiography for detecting pulmonary hypertension in severe COPD.Chest,2014,145:824-832.
4. 高新海,徐仲卿,趙文穗. 血漿氨基末端腦鈉肽水平與不同程度慢性阻塞性肺疾病肺動脈高壓的相關性. 廣東醫學,2011,32:1150-1151.
5. 王同生,毛毅敏,孫玉霞,等. 白介素-6 和內皮素-1 在慢性阻塞性肺疾病合并肺動脈高壓患者中的表達. 實用醫學雜志,2012,28:1977-1979.
6. Chaouat A,Savale L,Chouaid C,et al. Role for interleukin-6 in COPD-related pulmonary hypertension. Chest,2009,136:678-687.
7. MacIntyre N,Huang YC. Acute exacerbations and respiratory failure in chronic obstructive pulmonary disease. Proc Am Thorac Soc,2008,5:530-535.
8. 荊志成. 2010 年中國肺高血壓診治指南.中國醫學前沿雜志 (電子版),2011,3:62-81.
9. Wells JM,Washko GR,Han MK,et al. Pulmonary arterial enlargement and acute exacerbations of COPD. N Engl J Med,2012,367:913-921.
10. 劉鵬,郭順林,雷軍強,等. 慢性阻塞性肺疾病相關肺動脈高壓的多層螺旋CT評價. 中華結核和呼吸雜志,2012,35:264-268.
11. 高靳,余建群,白紅利,等. 慢性阻塞性肺部疾病病程與肺動脈直徑變化關系的多層螺旋CT評價. 實用放射學雜志,2009,25:332-337.
12. Committee GS. Global strategy for the diagnosis,management,and prevention of chronic obstructive pulmonary disease (updated 2013). www.goldcopd.org.
13. Buist AS,McBurnie MA,Vollmer WM,et al. International variation in the prevalence of COPD (the BOLD Study):a population-based prevalence study.Lancet,2007,370:741-750.
14. Zhong N,Wang C,Yao W,et al. Prevalence of chronic obstructive pulmonary disease in China:a large,population-based survey. Am J Respir Crit Care Med,2007,176:753-760.
15. Jensen HH,Godtfredsen NS,Lange P,et al. Potential misclassification of causes of death from COPD. Eur Respir J,2006,28:781-785.
16. Sims MW,Margolis DJ,Localio AR,et al. Impact of pulmonary artery pressure on exercise function in severe COPD. Chest,2009,136:412-419.
17. Kessler R,Faller M,Fourgaut G,et al. Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med,1999,159:158-164.
18. Parola D,Romani S,Petroianni A,et al. Treatment of acute exacerbations with non-invasive ventilation in chronic hypercapnic COPD patients with pulmonary hypertension. Eur Rev Med Pharmacol Sci,2012,16:183-191.
19. Minai OA,Chaouat A,Adnot S. Pulmonary hypertension in COPD:epidemiology,significance,and management pulmonary vascular disease:the global perspective. Chest,2010,137(6 Suppl):39S-51S.
20. Hoeper MM,Lee SH,Voswinckel R,et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol,2006,48:2546-2552.
21. Hill NS,Klinger JR,Warburton RR,et al. Brain natriuretic peptide:possible role in the modulation of hypoxic pulmonary hypertension.Am J Physiol,1994,266:308-315.
22. Inoue Y,Kawayama T,Iwanaga T,et al. High plasma brain natriuretic peptide levels in stable COPD without pulmonary hypertension or cor pulmonale. Intern Med,2009,48:503-512.
23. Sormunen P,Kallio MJ,Kili IT,et al.C-reactive protein is useful in distinguishing Gram stain negative bacterial meningitis from viral meningitis in children.Pediater,1999,134:725-729.
24. 王維,黃志峰,鄧穗德.2 型糖尿病患者血清超敏C反應蛋白的表達特性.現代醫院,2005,5:20-22.
25. 趙宇.超敏C反應蛋白在慢性阻塞性肺疾病并發肺動脈高壓中的意義.實用醫技雜志,2008,15:2761-2763.
26. Humbert M,Monti G,Brenot F,et al.Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension.Am J Respir Crit Care,1995,151:1628-1631.
27. Golembeski SM,West J,Tada Y,et al. Interleukin-6 causes mild pulmonary hypertension and augments hypoxia-induced pulmonary hypertension in mice. Chest,2005,128(6 Suppl):572S-573S.
28. Joppa P,Petrasiva D,Stancak B,et al. Systemic inflammation in patients with COPD and pulmonary hypertension. Chest,2006,130:326-333.
29. Guignabaert C,Raffestin B,Benferhat R,et al.Serotonin transporter inhibition prevents and reverses monocrotaline induced pulmonary hypertension in rats. Circulation,2005,111:2812-2819.

Previous Article
The Effectiveness of Peak Flow Meter in COPD Screening
Next Article
Effects of Perindopril on Expression of PI3K and Lung Function in COPD Rats

Chinese Journal of Respiratory and Critical Care Medicine

The Relevance of the Ratio of Pulmonary Arterial Diameter to Aortic Diameter Exceeding One with Brain Natriuretic Peptide and Inflammatory Factors in Patients with Acute Exacerbation of COPD

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content